Breaks Categories: News

FridayMar 24, 2017 11:18 am

NetworkNewsBreaks – Xenon Pharmaceuticals, Inc. (NASDAQ: XENE) Shares Dive; XEN801 Disappoints in Phase 2 Clinical Trial

Shares of Xenon Pharmaceuticals (NASDAQ: XENE) are down 51% after the company reported topline efficacy results from the phase 2 clinical trial to evaluate the efficacy, safety, tolerability and systemic exposure of XEN801 for the treatment of moderate to severe facial acne. Trial results show that XEN801 did not demonstrate a statistically significant difference from vehicle placebo in its primary endpoint of the percent change in total lesion count from baseline to week 12. Results also show that XEN801 did not demonstrate statistical significance relative to key secondary efficacy endpoints. “Despite the good scientific and preclinical rationale to pursue SCD1…

Continue Reading

ThursdayMar 23, 2017 2:52 pm

NetworkNewsBreaks – MGX Minerals, Inc. (MGXMF) Enters Agreement to Acquire Working Interest in Paradox Basin

Diversified mining company MGX Minerals, Inc. (OTC: MGXMF) today announced its entry into a joint operating agreement with a private vendor to act as operator and acquire a 75 percent working interest in certain underlying oil and gas leases located contiguous to MGX’s Lisbon Valley petrolithium project. The agreement calls for payments totaling $2 million due on or before September 1, 2018. An accelerated payment schedule reflecting discounted payments is also outlined in the agreement terms. Per the news release, the related leases cover portions of San Juan County, Utah, and San Miguel County, Colorado, including access to the brine-bearing…

Continue Reading

ThursdayMar 23, 2017 1:41 pm

NetworkNewsBreaks – ProBility Media Corp. (PBYA) Reports Record Sales for Fiscal Quarter Ended January 31, 2017

Education technology company ProBility Media Corp. (OTCQB: PBYA) today announced its filing of Form 10-Q for its fiscal first quarter ended January 31, 2017. Notably, the company achieved its third consecutive quarter of year-over-year revenue growth, reporting a 13 percent year-over-year increase to $1 million for the three-month period. “We would like to congratulate and thank the ProBility team for continuing to hit record sales, in addition to many other extraordinary accomplishments achieved over the last year,” Evan Levine, Noah Davis and Steven Plumb, executive management of ProBility Media, noted in a joint statement in the news release. “Through enthusiastic…

Continue Reading

ThursdayMar 23, 2017 12:57 pm

NetworkNewsBreaks – Atossa Genetics, Inc. (NASDAQ: ATOS) Opens Enrollment in Study of Endoxifen; Shares Down

Shares of Atossa Genetics (NASDAQ: ATOS) are 10% lower after the company this morning said that it has opened enrollment of a phase 1 study of endoxifen. Endoxifen is an active metabolite of tamoxifen, an FDA-approved drug for breast cancer. The phase 1 study is a placebo-controlled, repeat dose study of 48 healthy female volunteers. The objective is to assess the pharmacokinetics of proprietary formulations of both oral and topical endoxifen dosage forms over 28 days, as well as to assess safety and tolerability. To view the full press release, visit: http://nnw.fm/1Z9Fg About Atossa Genetics Atossa Genetics Inc., is a…

Continue Reading

ThursdayMar 23, 2017 9:38 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) CEO Featured in Audio Interview with NetworkNewsWire

Multifaceted financial news and publishing company NetworkNewsWire this morning announced the online availability of a new audio interview with India Globalization Capital, Inc. (NYSE MKT: IGC) CEO Ram Mukunda. In the interview, Mukunda discusses IGC’s operations and targeted market, as well as leading formulations currently in the company’s development pipeline. “This is a very exciting time for us, an exciting opportunity,” Mukunda noted in the interview. “We believe that we have first-mover advantage in combination therapy, as very few companies are actually working on cannabis-based pharmaceuticals and within that space we believe that we are the only ones working on…

Continue Reading

WednesdayMar 22, 2017 2:38 pm

NetworkNewsBreaks – InMed Pharmaceuticals (IMLFF) Featured in Forbes Article Discussing Unique Cannabinoid Manufacturing System and Database

InMed Pharmaceuticals (OTCQB: IMLFF) was recently featured in a Forbes article highlighting the company's cannabinoid manufacturing system and database, which is used to map different compounds of cannabinoids to the various diseases they are able to treat. According to the article, InMed’s database appeals to other biotech companies who are now willing to purchase the information. Using its database, InMed has been able to identify two new cannabinoid therapies. Additionally, the company has created a method of biosynthesis for cannabinoids that is comparable to the system used to create synthetic insulin for diabetic patients. The company begins with the cannabinoid…

Continue Reading

WednesdayMar 22, 2017 12:29 pm

NetworkNewsBreaks – United Health Products, Inc. (UEEC) Covered at SeeThruEquity

SeeThruEquity has issued a preliminary coverage report on United Health Products (OTCQB: UEEC). The report follows the company’s recently filed application with the FDA to expand use indications for its lead product candidate, Hemostyp®, an all-natural hemostatic agent that has demonstrated the ability to quickly control bleeding from open wounds and body cavities. Hemostyp® Topical Hemostatic Dressing is FDA approved as a Class 1 device and is sold in prescription and over-the-counter forms. If approved by the FDA, the indications for Hemostyp® would be expanded to include use in general surgery, opening a new form of revenue for the company.…

Continue Reading

WednesdayMar 22, 2017 11:18 am

NetworkNewsBreaks – TapImmune, Inc. (NASDAQ: TPIV) Announces Participation in Two Upcoming Investor and Industry Conferences

Clinical-stage immuno-oncology company TapImmune, Inc. (NASDAQ: TPIV) today announced plans to participate in two upcoming investor and industry conferences. First, Dr. Glynn Wilson, chairman and CEO of TapImmune, will be offering an overview of the company’s business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York City. Wilson’s presentation is scheduled for 10:35 am ET on Tuesday, March 28, 2017. The full presentation will be webcast live and archived for future viewing at http://tapimmune.com/events. Second, Dr. John Bonfiglio, president and chief operating…

Continue Reading

TuesdayMar 21, 2017 10:37 am

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Subsidiary Teams with Planet Payment to Offer Multi-Currency Pricing

Mobile payment technology company Net Element, Inc. (NASDAQ: NETE) this morning announced that its Unified Payments subsidiary has entered into a strategic partnership with Planet Payment, Inc. (NASDAQ: PLPM), a leading provider of international and multi-currency payment processing services. Through this agreement, Unified Payments will offer Planet Payment’s Multi-Currency Pricing to its portfolio of online merchants, enabling them to more effectively expand into foreign markets by displaying pricing and accepting payments in a variety of local currencies. “We are excited to form this partnership with Planet Payment to bring our online merchants the ability to price in multiple currencies and…

Continue Reading

TuesdayMar 21, 2017 9:58 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Files Provisional Patent for Treatment of Eating Disorders Using Cannabis Extracts

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its filing of a provisional patent for the treatment of multiple types of eating disorders by a method and combination of cannabis extracts and other compounds. Should this filing result in the issuance of a patent, IGC intends to develop its IGC-506 candidate for both human and veterinary use. “The development of cannabis-based combination therapies represents a large, unique opportunity, and we believe we are the first mover in this emerging specialty-pharmaceutical sector,” Ram Mukunda, chief executive officer…

Continue Reading